ASGR1 Antibody TLR8 Agonist Conjugate for Liver Viral Infection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral medications for treating Hepatitis B and Hepatitis C infections are not always effective due to viral immunological ignorance, where viruses evade detection by the innate immune system.
Innovation Solution
A myeloid cell agonist conjugate comprising an anti-asialoglycoprotein receptor 1 (ASGR1) antibody or antigen-binding fragment conjugated with a myeloid cell agonist, specifically a TLR8 agonist, to activate immune cells and enhance immune response against viral infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiviral medications are used to treat Hepatitis B and Hepatitis C infections, then viral replication can be suppressed, but treatment effectiveness is limited due to viral immunological ignorance and evasion of immune detection
Solution Approach 1:
The patent combines an anti-ASGR1 antibody with a TLR8 agonist into a conjugate structure, creating a composite therapeutic agent that simultaneously achieves liver targeting and immune activation. The antibody component directs the conjugate to hepatocytes via ASGR1 binding, while the TLR8 agonist component activates myeloid cells to overcome viral immune evasion, resolving the contradiction between treatment effectiveness and viral immune evasion.
Solution Approach 2:
The conjugate acts as an intermediary that bridges the gap between passive antibody targeting and active immune stimulation. By linking the antibody and TLR8 agonist, the conjugate mediates both specific liver cell targeting and robust immune activation, enabling the immune system to detect and respond to viruses that would otherwise remain undetected.
2Reliability
If the immune system is activated to detect viruses, then immune response can be enhanced, but liver damage may occur as a side effect
Solution Approach 1:
The conjugate enables localized immune activation specifically at the liver site by targeting ASGR1-expressing hepatocytes. The TLR8 agonist is delivered precisely to liver-resident myeloid cells through the antibody's specific binding to ASGR1, thereby activating the immune response locally at the infection site while minimizing systemic immune activation and potential liver damage.
Solution Approach 2:
The anti-ASGR1 antibody serves as a protective intermediary that guides the TLR8 agonist specifically to hepatocytes, preventing indiscriminate immune activation. This targeted delivery mechanism ensures that immune stimulation occurs only where viruses are present, reducing the risk of off-target liver damage while maintaining effective antiviral immunity.
3Reliability
If a conjugate structure is created to combine targeting and immune activation functions, then therapeutic efficacy is improved, but device complexity increases
Solution Approach 1:
The patent merges two distinct therapeutic functions—liver targeting via anti-ASGR1 antibody and immune activation via TLR8 agonist—into a single conjugate molecule. This consolidation integrates targeting and effector functions into one unified therapeutic agent, improving therapeutic efficacy while avoiding the need for separate administration of multiple agents, thereby managing complexity through functional integration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugate effectively induces TNF-α production, activates immune cells, and promotes anti-viral cytokine responses, leading to reduced viral DNA and HBsAg antigen levels, and anti-HBsAg seroconversion in infected mice without liver damage.
Implementation Method 1
an anti-asialoglycoprotein receptor 1 (ASGR1) antibody or antigen-binding fragment
Implementation Method 2
a myeloid cell agonist, specifically a TLR8 agonist, to activate immune cells and enhance immune response
Data Source
AI summary
The disclosure provides conjugates of anti-ASGR1 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating liver viral infections with the conjugates. The disclosure also provides for anti-ASGR1 antibodies or antigen binding fragments thereof and methods for using the antibodies or antigen binding fragments thereof in treating liver viral infections.